Short answer
Bio-Techne (TECH) filed an 8-K current report with the SEC on September 23, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Merger approved by shareholders, clearing a key condition for Merck KGaA’s acquisition of Bio-Techne.
Bio-Techne 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Merger approved by shareholders, clearing a key condition for Merck KGaA’s acquisition of Bio-Techne
- 121.93M votes for versus 1.21M against, with 30,610 abstentions
- Merck KGaA to own Bio-Techne as a wholly owned subsidiary after merger completion
- 78.55% of outstanding shares represented at the September 23, 2026 special meeting
- Executive merger-related compensation rejected in non-binding vote, 25.91M for versus 96.41M against
Item 7.01 · Regulation FD Disclosure
- Item 7.01 contains only standard Regulation FD non-incorporation language
- No substantive business, financial, or investor-impacting disclosure in the provided text
Item EX-99.1 · Exhibit EX-99.1
- Shareholders approved Merck KGaA’s proposed acquisition, removing a key transaction condition
- Hart-Scott-Rodino waiting period expired September 18, 2026, reducing U.S. antitrust execution risk
- Closing expected by late 2026 or early 2027, subject to remaining regulatory approvals and customary conditions
- Transaction offers shareholders near-term cash value, while completion remains exposed to regulatory and closing risks
- Bio-Techne generated over $1.2 billion fiscal 2025 net sales and employs more than 3,000 people
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bio-Techne 8-K filings
Get the next TECH 8-K as it lands
Follow TECH for push alerts, or ask the research agent what this filing means.